Sarah Cannon July 01, 2013

"

NASHVILLE, TN and WILMINGTON, DE, July 1, 2013 – Sarah Cannon Research Institute (SCRI) and AstraZeneca (AZ) announced today a collaboration in the field of personalized medicine to support development of new AstraZeneca oncology compounds. Specifically, the parties will work together on molecular profiling to classify tissue based upon genetic profiles for the purpose of treating cancers and predicting response to therapy.